{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:55Z","timestamp":1787671915636,"version":"build-2736575974"},"reference-count":59,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High\u2010impact site plaque psoriasis is difficult to treat. Icotrokinra, an oral peptide with high specificity for the interleukin (IL)\u201023 receptor, demonstrated significantly higher rates of high\u2010impact site psoriasis clearance, versus placebo, with no safety signals, through Week (W)16.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Report clinical response rates and safety through 1\u2009year of icotrokinra treatment in participants with high\u2010impact site plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants (\u226512\u2009years of age; psoriasis body surface area \u22651%; Investigator's Global Assessment [IGA] \u22652) with at least moderate scalp, genital or hand\/foot psoriasis were randomized (2:1) to once\u2010daily icotrokinra 200\u2009mg (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009208) or placebo (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009103), with placebo\u2010to\u2010icotrokinra transition at W16 (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200992). Rates (using nonresponder imputation) of achieving clear\/almost clear (0\/1) or clear (0) overall skin (IGA), genital (static Physician's Global Assessment of genitalia [sPGA\u2010G]), hand\/foot (hf\u2010PGA) psoriasis and absent\/very mild (0\/1) or absent (0) scalp psoriasis (scalp\u2010specific\u2010IGA [ss\u2010IGA]), modified Nail Psoriasis Severity Index (mNAPSI) percent improvement and safety were assessed through W52.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty\u2010eight per cent (275\/311) of participants completed treatment through W52. In icotrokinra\u2010randomized participants, response rates increased through W24 and were durable through W52 for overall psoriasis clearance (IGA 0\/1 range: 67%\u201370%) and across high\u2010impact sites (ss\u2010IGA 0\/1: 72%\u201378%; sPGA\u2010G 0\/1: 85%\u201390%; hf\u2010PGA 0\/1: 54%\u201362%); responses were consistent among placebo\u2010randomized participants after transitioning to icotrokinra. High proportions of icotrokinra\u2010randomized participants achieved complete clearance during W24\u201352 (IGA 0: 44%\u201351%; ss\u2010IGA 0: 57%\u201366%; sPGA\u2010G 0: 73%\u201384%; hf\u2010PGA 0: 44%\u201358%). Mean mNAPSI improvement increased from W16 (33%) to W52 (62%). Exposure\u2010adjusted rates of participants with \u22651 adverse event (AE) or serious AE through W16 were similar between icotrokinra and placebo, with no increase in AE rates or occurrence of a safety signal through W52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Icotrokinra demonstrated high and durable rates of psoriasis clearance across high\u2010impact sites, with a favourable safety profile, through 1\u2009year.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70471","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:24:41Z","timestamp":1779535481000},"page":"1502-1514","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durability of response to icotrokinra for high\u2010impact site psoriasis: 1\u2010year\n                    <scp>ICONIC<\/scp>\n                    \u2010\n                    <scp>TOTAL<\/scp>\n                    findings"],"prefix":"10.1111","volume":"40","author":[{"given":"Richard B.","family":"Warren","sequence":"first","affiliation":[{"name":"Northern Care Alliance NHS Foundation Trust &amp; Division of Musculoskeletal and Dermatological Sciences, Dermatology Centre, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology  Peterborough Ontario Canada"},{"name":"Department of Medicine Queen's University  Kingston Ontario Canada"},{"name":"Probity Medical Research  Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[{"name":"Austin Institute for Clinical Research Sanova Dermatology  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-6587","authenticated-orcid":false,"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"Innovaderm Research  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Huei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chang Gung Memorial Hospital and College of Medicine, Chang Gung University  Taoyuan City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6773-4645","authenticated-orcid":false,"given":"Julien","family":"Ringuet","sequence":"additional","affiliation":[{"name":"Centre de Recherche Dermatologique du Qu\u00e9bec M\u00e9tropolitain  Quebec Quebec Canada"},{"name":"Department of Dermatology McGill University  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Dermatology Practice Dr Matthias Hoffmann  Witten Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt am Main  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology UT Southwestern Medical Center and O'Donnell School of Public Health  Dallas Texas USA"},{"name":"Division of Rheumatology, Department of Medicine UT Southwestern Medical Center and O'Donnell School of Public Health  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9198-9149","authenticated-orcid":false,"given":"Jessica H.","family":"Rubens","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Fan","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming\u2010Chun","family":"Hsu","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  West Chester Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Malvern Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u2010Wen","family":"Yang","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M. C.","family":"DeKlotz","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eingun James","family":"Song","sequence":"additional","affiliation":[{"name":"Frontier Dermatology  Mill Creek Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.80718"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.890"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00536-6"},{"key":"e_1_2_14_6_1","volume-title":"Nail psoriasis","author":"Muneer H","year":"2024"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01456-5"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247549"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.026"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09505.x"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_2_14_14_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"5","author":"Sbidian E","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253048"},{"key":"e_1_2_14_16_1","unstructured":"Stein GoldL SoungJ ConklinL TaylorM ConklinL LewisJ et\u00a0al.Unmet needs of adults with psoriasis and clinicians treating psoriasis in the US. Poster presented at American Acadamy of Dermatology Innovation Academy; July 10\u201013 2025; Chicago IL USA. Available from:https:\/\/eposters.aad.org\/archives\/IA2025\/70041. Accessed 09 Nov 2025."},{"key":"e_1_2_14_17_1","unstructured":"Amgen Inc.OTEZLA (Apremilast). U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/205437Orig1s013correctedlbl.pdf.2024."},{"key":"e_1_2_14_18_1","unstructured":"Bristol\u2010Myers Squibb.SOTYKTU (deucravacitinib). U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214958s000lbl.pdf.2022."},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0"},{"key":"e_1_2_14_21_1","unstructured":"Janssen Biotech Inc.TREMFYA (guselkumab). U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761061s024lbl.pdf.2025."},{"key":"e_1_2_14_22_1","unstructured":"Janssen Biotech Inc.STELARA (ustekinumab). U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125261s167lbl.pdf.2025."},{"key":"e_1_2_14_23_1","unstructured":"Sun Pharmaceutical Industries Inc.ILUMYA (tildrakizumab\u2010asmn). U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761067s018lbl.pdf.2025."},{"key":"e_1_2_14_24_1","unstructured":"AbbVie Inc.SKYRIZI (risankizumab\u2010rzaa). U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761105s039 761262s011lbl.pdf.2025"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00483-2"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01454-7"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.193563"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67371-5"},{"key":"e_1_2_14_29_1","unstructured":"Janssen Biotech Inc.ICOTYDE (icotrokinra). Johnson & Johnson website. Available from:https:\/\/www.jnjlabels.com\/package\u2010insert\/product\u2010monograph\/prescribing\u2010information\/ICOTYDE\u2010pi.pdf.2026."},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01576-4"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504187"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500155"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0793"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051731"},{"key":"e_1_2_14_36_1","first-page":"793","article-title":"The static physician's global assessment of genitalia: a clinical outcome measure for the severity of genital psoriasis","volume":"16","author":"Merola JF","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2523373"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.12.898"},{"key":"e_1_2_14_40_1","first-page":"123","article-title":"The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell SE","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1364694"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14464"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0213-2"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0212-3"},{"key":"e_1_2_14_46_1","first-page":"425","article-title":"Hard\u2010to\u2010treat areas in psoriasis: an underevaluated part of the disease","volume":"15","author":"Lupulescu AM","year":"2025","journal-title":"Life (Basel)"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S169389"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338858"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.135470"},{"key":"e_1_2_14_50_1","unstructured":"SoungJ HongC EhstB et\u00a0al.Treatment of plaque psoriasis involving high\u2010impact sites with icotrokinra: subgroup analyses of the phase 3 ICONIC\u2010LEAD trial. Poster presented at American Acadamy of Dermatology Innovation Academy; July 10\u201013 2025; Chicago IL USA. Available from:https:\/\/eposters.aad.org\/archives\/IA2025\/69245."},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308713"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.076"},{"key":"e_1_2_14_53_1","doi-asserted-by":"crossref","unstructured":"SoungJ CuiY BissonnetteR LebwohlMG CanteroAG PinterA et\u00a0al.Maintenance of response with Icotrokinra a targeted Oral peptide for the treatment of moderate\u2010to\u2010severe plaque psoriasis. European Academy of Dermatology and Venereology; September 17\u201020 2025; Paris France.","DOI":"10.1016\/j.jaad.2026.05.048"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01012-z"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01544-6"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1521"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3353"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1749546"},{"key":"e_1_2_14_59_1","unstructured":"ArmstrongA MahmoudH FeghelmL YangYW DisherT.Comparative analysis of icotrokinra and approved advanced treatments for achievement of completely clear skin in patients with moderate\u2010to\u2010severe psoriasis: a systematic literature review and network meta\u2010analysis. Poster presented at Maui Derm Hawaii; January 25\u201029 2026; Maui HI USA."},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16966"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:05:36Z","timestamp":1787670336000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/jdv.70471"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70471","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"2026-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}